Stock listing
NASDAQ:MRKR Marker Therapeutics, Inc. Stock
Home listing (NASDAQ) of Marker Therapeutics, Inc.
Follow Marker Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:MRKR
$1.09 USD -0.23 (-17.4%)
Close on Nov 20, 2026
- Day range
- $1.09 – $1.45 USDNov 20, 2026
- Volume
- 1.88M sharesNov 20, 2026
- Market cap
- $18.17M USDAt the close on Nov 20, 2026 · price × 16.67M shares outstanding
- 52-week range
- $0.81 – $2.46 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $879,874 USDMedian day 91,050 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:MRKR · Home | $1.09 USD | -0.23 (-17.4%) | 1,877,767 | $1.34 | $1.45 | $1.09 | $1.32 | Close on Nov 20, 2026 |
| Frankfurt:GX1 | €0.969 EUR | -0.330 (-25.4%) | — | €1.054 | €1.177 | €0.966 | €1.299 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:MRKR · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.09 | -0.23 | -17.4% | $1.34 | $1.45 | $1.09 | 1,877,767 | |
| $1.32 | +0.467 | +54.7% | $1.02 | $1.68 | $0.984 | 36,085,341 | |
| $0.853 | +0.017 | +2.0% | $0.844 | $0.92 | $0.835 | 105,843 | |
| $0.837 | +0.008 | +1.0% | $0.871 | $0.903 | $0.81 | 203,542 | |
| $0.829 | -0.041 | -4.8% | $0.898 | $0.912 | $0.82 | 135,857 | |
| $0.87 | -0.03 | -3.3% | $0.92 | $0.93 | $0.87 | 76,100 | |
| $0.90 | -0.05 | -5.3% | $0.95 | $0.97 | $0.90 | 140,800 | |
| $0.95 | 0.00 | 0.0% | $0.95 | $0.98 | $0.94 | 28,400 | |
| $0.95 | -0.04 | -4.0% | $1.01 | $1.03 | $0.95 | 53,000 | |
| $0.99 | +0.10 | +11.2% | $0.93 | $1.05 | $0.87 | 231,400 | |
| $0.89 | -0.01 | -1.1% | $0.90 | $0.95 | $0.89 | 50,400 | |
| $0.90 | -0.11 | -10.9% | $1.00 | $1.03 | $0.88 | 189,000 | |
| $1.01 | +0.03 | +3.1% | $0.99 | $1.05 | $0.99 | 93,400 | |
| $0.98 | +0.08 | +8.9% | $0.91 | $1.00 | $0.89 | 94,600 | |
| $0.90 | -0.08 | -8.2% | $0.96 | $0.97 | $0.88 | 265,700 | |
| $0.98 | -0.03 | -3.0% | $1.03 | $1.04 | $0.96 | 67,600 | |
| $1.01 | +0.01 | +1.0% | $0.99 | $1.07 | $0.98 | 72,900 | |
| $1.00 | +0.05 | +5.3% | $0.96 | $1.07 | $0.90 | 86,900 | |
| $0.95 | +0.04 | +4.4% | $0.92 | $0.98 | $0.89 | 103,900 | |
| $0.91 | -0.05 | -5.2% | $0.95 | $1.04 | $0.87 | 217,600 | |
| $0.96 | -0.11 | -10.3% | $1.07 | $1.12 | $0.96 | 114,400 | |
| $1.07 | -0.06 | -5.3% | $1.17 | $1.17 | $1.07 | 91,500 | |
| $1.13 | -0.03 | -2.6% | $1.16 | $1.27 | $1.13 | 149,900 | |
| $1.16 | -0.04 | -3.3% | $1.19 | $1.24 | $1.11 | 209,400 | |
| $1.20 | +0.16 | +15.4% | $1.09 | $1.20 | $1.05 | 578,800 | |
| $1.04 | +0.12 | +13.0% | $1.02 | $1.20 | $1.00 | 1,146,100 | |
| $0.92 | +0.03 | +3.4% | $0.96 | $0.96 | $0.88 | 120,200 | |
| $0.89 | -0.03 | -3.3% | $0.92 | $0.95 | $0.89 | 65,800 | |
| $0.92 | -0.09 | -8.9% | $1.03 | $1.03 | $0.91 | 175,200 | |
| $1.01 | +0.04 | +4.1% | $0.98 | $1.03 | $0.98 | 107,800 | |
| $0.97 | +0.02 | +2.1% | $0.93 | $1.00 | $0.93 | 91,200 | |
| $0.95 | -0.09 | -8.7% | $1.04 | $1.05 | $0.95 | 96,900 | |
| $1.04 | +0.03 | +3.0% | $1.03 | $1.06 | $1.03 | 37,500 | |
| $1.01 | -0.05 | -4.7% | $1.07 | $1.07 | $1.00 | 77,100 | |
| $1.06 | +0.01 | +1.0% | $1.08 | $1.09 | $1.05 | 73,500 | |
| $1.05 | 0.00 | 0.0% | $1.06 | $1.08 | $1.02 | 100,300 | |
| $1.05 | -0.02 | -1.9% | $1.08 | $1.09 | $0.98 | 127,500 | |
| $1.07 | -0.03 | -2.7% | $1.12 | $1.14 | $1.07 | 38,400 | |
| $1.10 | -0.03 | -2.7% | $1.14 | $1.16 | $1.08 | 90,900 | |
| $1.13 | -0.02 | -1.7% | $1.12 | $1.15 | $1.07 | 164,300 | |
| $1.15 | -0.04 | -3.4% | $1.22 | $1.22 | $1.15 | 29,600 | |
| $1.19 | -0.05 | -4.0% | $1.26 | $1.31 | $1.15 | 141,600 | |
| $1.24 | +0.02 | +1.6% | $1.24 | $1.27 | $1.23 | 64,900 | |
| $1.22 | +0.02 | +1.7% | $1.18 | $1.24 | $1.18 | 38,700 | |
| $1.20 | +0.02 | +1.7% | $1.18 | $1.22 | $1.18 | 24,200 | |
| $1.18 | 0.00 | 0.0% | $1.19 | $1.23 | $1.17 | 47,300 | |
| $1.18 | +0.04 | +3.5% | $1.13 | $1.23 | $1.13 | 60,600 | |
| $1.14 | -0.03 | -2.6% | $1.17 | $1.18 | $1.13 | 35,900 | |
| $1.17 | 0.00 | 0.0% | $1.17 | $1.23 | $1.15 | 12,000 | |
| $1.17 | +0.02 | +1.7% | $1.16 | $1.23 | $1.16 | 17,400 | |
| $1.15 | -0.05 | -4.2% | $1.20 | $1.25 | $1.10 | 59,400 | |
| $1.20 | -0.01 | -0.8% | $1.21 | $1.23 | $1.18 | 55,500 | |
| $1.21 | -0.07 | -5.5% | $1.29 | $1.29 | $1.21 | 71,200 | |
| $1.28 | +0.10 | +8.5% | $1.19 | $1.39 | $1.19 | 200,300 | |
| $1.18 | -0.06 | -4.8% | $1.25 | $1.31 | $1.18 | 35,300 | |
| $1.24 | -0.01 | -0.8% | $1.24 | $1.31 | $1.22 | 43,400 | |
| $1.25 | -0.05 | -3.8% | $1.25 | $1.33 | $1.24 | 167,600 | |
| $1.30 | -0.03 | -2.3% | $1.31 | $1.34 | $1.26 | 21,000 | |
| $1.33 | -0.04 | -2.9% | $1.37 | $1.41 | $1.31 | 59,500 | |
| $1.37 | -0.09 | -6.2% | $1.50 | $1.50 | $1.35 | 84,800 | |
| $1.46 | +0.01 | +0.7% | $1.45 | $1.50 | $1.40 | 24,500 | |
| $1.45 | -0.07 | -4.6% | $1.52 | $1.59 | $1.45 | 33,800 | |
| $1.52 | +0.02 | +1.3% | $1.50 | $1.60 | $1.48 | 146,700 | |
| $1.50 | +0.11 | +7.9% | $1.44 | $1.53 | $1.41 | 238,000 | |
| $1.39 | +0.17 | +13.9% | $1.25 | $1.44 | $1.25 | 99,400 | |
| $1.22 | -0.07 | -5.4% | $1.28 | $1.32 | $1.19 | 80,600 |
Splits
5 splits since 2007 · NASDAQ:MRKR · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation | |
| 1-for-12 | Consolidation | |
| 1-for-100 | Consolidation | |
| 1-for-10 | Consolidation | |
| 2-for-5 | Consolidation |
- Ticker
- NASDAQ:MRKR
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study
Latest news
Marker Therapeutics Awarded $16.2 Million CPRIT Grant to Advance MT-601 in Phase 2 APOLLO Study
Nov 19, 2026
Closed $1.32 (+54.7%) on Nov 19, 2026
Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer
Oct 19, 2026
Closed $1.20 (+15.4%) on Oct 19, 2026
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
Mar 18, 2026
Closed $1.34 (-1.5%) on Mar 18, 2026
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Feb 18, 2026
Closed $1.50 (+3.4%) on Feb 18, 2026
Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology
Jan 26, 2026
Closed $1.87 (-11.0%) on Jan 26, 2026
Marker Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 6 in the last 12 months · 106 in all · newest Nov 19, 2026 · oldest 2019
- Calls
- 1 call with a replay · 1 with a transcript · latest Feb 16, 2022
- Decks
- 14 decks · latest November 2025
Where Marker Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:MRKR · Home listing · This page | NASDAQ | United States | USD |
| gettex:GX1 | gettex | Germany | EUR |
| BOATS:MRKR | BOATS | United States | USD |
| Frankfurt:GX1 | Frankfurt | Germany | EUR |
| Munich:GX1 | Munich | Germany | EUR |
Valuation
EV/sales 4.9× against a median of 15.6×: 2nd lowest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $9.13M USD
- P/E
- Loss
- EV/sales
- 4.9×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 1.7×
- Gross margin
- Not reported
- Operating margin
- −504.7%
- Net margin
- −461.1%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.49
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Marker Therapeutics, Inc. · NASDAQ:MRKR | US$18.17M | US$9.13M | n/a | 4.9× | n/a | 1.7× | −461.1% | 0.0× | 1.49 |
| Adicet Bio, Inc. · NASDAQ:ACET | US$20.03M | US$5.02M | n/a | n/a | n/a | 0.2× | n/a | 0.1× | 2.02 |
| IGC Pharma, Inc. · AMEX:IGC | US$19.60M | US$19.19M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | 1.09 |
| Provectus Biopharmaceuticals, Inc. · OTC:PVCT | US$19.12M | US$18.94M | n/a | n/a | n/a | n/a | n/a | n/a | -0.21 |
| LeonaBio, Inc. · NASDAQ:LONA | US$19.03M | −US$12.82M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.04 |
| Cocrystal Pharma, Inc. · NASDAQ:COCP | US$18.30M | US$14.69M | n/a | 33.8× | n/a | 6.8× | n/a | 0.5× | 1.21 |
| Syntara Limited · ASX:SNT | US$18.20M | US$9.23M | n/a | 2.0× | n/a | 1.7× | −129.8% | 0.0× | n/a |
| Resverlogix Corp. · TSX:RVX | US$18.01M | US$95.55M | n/a | n/a | n/a | n/a | n/a | n/a | 0.26 |
| SynCore Biotechnology Co., Ltd. · TPEX:4192 | US$16.80M | US$12.38M | n/a | 15.6× | n/a | 2.5× | −178.5% | 0.0× | n/a |
| Initiator Pharma A/S · OMXSTO:INIT | US$16.76M | US$15.67M | n/a | n/a | n/a | 13.4× | n/a | 1.1× | n/a |
| Neurotech International Ltd. · ASX:NTI | US$16.63M | US$15.06M | n/a | n/a | n/a | 41.1× | n/a | 0.0× | n/a |
| Median of the others | US$18.25M | US$14.87M | 15.6× | 2.8× | −154.2% | 0.0× | 1.07 |
Forecasts
3 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 7.87 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.56 · 2 analysts
- Revenue, year to Dec 2026
- 4.24M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Juan F. Vera | Chief Executive Officer & Co-Founder, Marker Therapeutics |
| Kathryn Penkus Corzo | President and Chief Operating Officer, bit.bio |
| Edmund Cheung | Vice President, Human Resources |
| Katharine Knobil | Chief Medical Officer, Altesa BioSciences, Inc. |
| Mary Newman | Head of Regulatory Affairs |
| Patricia Allison | Head of Clinical Operations |
Board
| Director | Role |
|---|---|
| David Eansor | Director |
| Juan F. Vera | Chief Executive Officer & Co-Founder, Marker Therapeutics |
| Katharine Knobil | Chief Medical Officer, Altesa BioSciences, Inc. |
| Kathryn Penkus Corzo | President and Chief Operating Officer, bit.bio |
| Steve Elms | Managing Partner, Aisling Capital |
Events
Calls
| Call | When | Status |
|---|---|---|
| Marker Therapeutics (NASDAQ:MRKR) Q2 2022 Earnings Call | Wed, Feb 16, 2022 · 5:00 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · After close | +1.0% |
| Q2 2026 | Aug 14, 2026 · After close | +1.8% |
| Q1 2026 | May 15, 2026 · After close | −2.1% |
| Q4 2025 | Mar 19, 2026 | 0.0% |
| Q3 2025 | Nov 13, 2025 · After close | +3.4% |
| Q2 2025 | Aug 14, 2025 · After close | +0.8% |
| Q1 2025 | May 15, 2025 · After close | −1.8% |
| Q4 2024 | Mar 24, 2025 · Before open | +2.4% |
| Q3 2024 | Nov 14, 2024 · After close | −12.3% |
| Q2 2024 | Aug 14, 2024 · After close | −5.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 15, 2024 · After close | −1.7% |
| Q4 2023 | Mar 26, 2024 · Before open | −10.7% |
| Q3 2023 | Nov 9, 2023 · After close | −8.4% |
| Q2 2023 | Aug 14, 2023 · After close | +25.8% |
| Q1 2023 | May 15, 2023 · After close | −3.6% |
| Q4 2022 | Mar 22, 2023 · Before open | −31.8% |
| Q3 2022 | Nov 10, 2022 · After close | 0.0% |
| Q2 2022 | Aug 11, 2022 · After close | −13.3% |
| Q1 2022 | May 13, 2022 · Before open | +6.5% |
| Q4 2021 | Mar 17, 2022 · After close | +2.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2025) | Investor deck | 20 slides | November 2025 |
| Investor Presentation (August 2025) | Investor deck | 28 slides | Aug 26, 2025 |
| Investor Presentation (August 2025) | Investor deck | 20 slides | Aug 26, 2025 |
| Investor Presentation (January 2024) | Investor deck | 21 slides | Jan 8, 2024 |
| Investor Presentation (March 2021) | Investor deck | 38 slides | Mar 16, 2021 |
| Technical Presentation (June 2020) | Technical | 40 slides | Jun 1, 2020 |
| Investor Presentation (September 2019) | Investor deck | 19 slides | Sep 24, 2019 |
| Technical Presentation (July 2019) | Technical | 32 slides | Jul 22, 2019 |
| Investor Presentation (April 2019) | Investor deck | 58 slides | April 2019 |
| Technical Presentation (February 2019) | Technical | 17 slides | Feb 25, 2019 |
All 14 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (February 2019) | Technical | 26 slides | Feb 25, 2019 |
| Technical Presentation (February 2019) | Technical | 22 slides | Feb 25, 2019 |
| Technical Presentation (2019) | Technical | 66 slides | 2019 |
| Technical Presentation (December 2018) | Technical | 41 slides | Dec 4, 2018 |
Financings
| Raise | Date |
|---|---|
| At-the-market programme of common stock Tranche closed: US$10M raised Use of proceeds: Extending the company's cash runway well into 2026 | Nov 14, 2025 |
| Private placement of common stock (or pre-funded warrants) and accompanying warrants Announced: US$16.1M · US$3.2 a share · Warrants at US$4.03 for 60 months · Canaccord Genuity +1 Dealers: Canaccord Genuity (lead), Brookline Capital Markets, a division of Arcadia Securities, LLC Buyers: Blue Owl Healthcare Opportunities; New Enterprise Associates (NEA); Aisling Capital Use of proceeds: Support clinical advancement of the Phase 1 APOLLO study of MT-601 in lymphoma, among other uses | Dec 19, 2024 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.55M | 6.59M | 3.31M | 3.51M | 0 | 500.0K | 213.2K | 206.0K | 183.1K | 0 |
| Cost of revenue | 13.5M | 10.4M | 12.0M | 3.16M | 18.9M | 12.8M | 124.0M | 5.25M | 0 | |
| Gross profit | -6.88M | -7.11M | -8.45M | -1.92M | -18.4M | -12.6M | -123.8M | -5.07M | 0 | |
| Research and development | 11.8M | 13.5M | 10.4M | 12.0M | 27.8M | 18.9M | 12.8M | 7.95M | 5.25M | 3.80M |
| Selling, general and administrative | 4.18M | 4.24M | 7.48M | 11.3M | 12.9M | 10.5M | 9.98M | 24.4M | 6.41M | 4.69M |
| Operating income | -12.9M | -11.1M | -14.6M | -19.8M | -39.5M | -28.9M | -22.5M | -148.2M | -11.5M | -8.49M |
| Depreciation and amortization | 2 | 2.79M | 2.79M | 2.15M | 485.6K | 105.1K | 0 | 11.5M | 8.49M | |
| EBITDA | -11.1M | -11.8M | -17.0M | -37.3M | -28.4M | -22.4M | -148.2M | 0 | 0 | |
| Interest expense | 15.1K | 5.70K | 148.7K | 0 | 0 | 0 | 0 | |||
| Income before tax | -12.2M | -10.7M | -14.0M | -19.8M | -41.9M | -28.7M | -21.4M | -148.0M | -11.0M | -2.46M |
| Income tax | -15.2K | 50.0K | 3.67K | -15.1K | -5.70K | -180.0K | -1.10M | 0 | 0 | 0 |
| Net income | -12.2M | -10.7M | -8.24M | -29.9M | -41.9M | -28.7M | -21.4M | -148.0M | -11.0M | -2.46M |
| Earnings per share, basic | -0.79 | -1.19 | -0.94 | -3.58 | -5.47 | -0.61 | -0.47 | -7.75 | -1.16 | -0.36 |
| Earnings per share, diluted | -0.79 | -1.19 | -0.94 | -3.58 | -5.47 | -0.61 | -0.47 | -7.75 | -1.16 | -0.72 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 16.1M | 19.2M | 15.1M | 11.8M | 42.4M | 21.4M | 43.9M | 61.7M | 5.13M | 7.85M |
| Short-term investments | 19.2T | |||||||||
| Receivables | 1.37M | 2.35M | 1.03M | 2.40M | 237 | 1.00M | 56.2K | 108.2K | ||
| Inventory | -988.1K | -1.00M | ||||||||
| Current assets | 19.1M | 22.0M | 17.1M | 16.6M | 46.0M | 24.4M | 45.5M | 62.0M | 5.18M | 7.92M |
| Property, plant and equipment | 12.3M | 12.3M | 10.4M | 418.0K | 147.7K | 0 | ||||
| Total assets | 19.1M | 22.0M | 17.1M | 34.4M | 68.1M | 45.6M | 46.4M | 62.1M | 5.18M | 7.92M |
| Accounts payable | 793.7K | 1.07M | 961.0K | 1.10M | 5.14M | 2.94M | 993.0K | 1.62M | 1.01M | 680.0K |
| Current liabilities | 2.27M | 3.46M | 3.07M | 7.78M | 12.9M | 6.40M | 1.99M | 2.80M | 1.52M | 1.74M |
| Total debt | 7.62M | 11.9M | 12.3M | 484.4K | 5.00K | 5.00K | ||||
| Total liabilities | 2.27M | 3.46M | 3.07M | 14.8M | 24.1M | 18.3M | 2.27M | 2.80M | 1.52M | 1.74M |
| Shareholders' equity | 16.8M | 18.6M | 14.1M | 19.6M | 44.0M | 27.3M | 44.1M | 59.3M | 3.66M | 6.18M |
| Shares outstanding | 16.7M | 10.7M | 8.90M | 8.40M | 8.30M | 50.7M | 45.7M | 45.4M | 10.6M | 8.40M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -12.0M | -10.9M | -16.4M | -27.0M | -27.3M | -20.0M | -18.3M | -14.5M | -8.44M | -6.51M |
| Capital spending | -1 | -4 | -1 | -3 | -3.13M | -9.25M | -375.0K | -147.7K | 0 | -147.7K |
| Free cash flow | -12.0M | -10.9M | -16.4M | -27.0M | -30.4M | -29.3M | -18.7M | -14.6M | -8.44M | -6.51M |
| Cash from investing | 18.7M | -4.95M | -3.13M | -9.25M | -375.0K | -147.7K | 0 | -147.7K | ||
| Cash from financing | 9.86M | 15.0M | 1.11M | 202.1K | 52.6M | 6.74M | 816.5K | 71.2M | 5.72M | 7.78M |
| Share buybacks | 6.74M | 816.5K | -71.7K | -310.5K | 0 | |||||
| Change in cash | -2.15M | 4.08M | 3.33M | 11.8M | 43.5M | -22.6M | -17.8M | 56.6M | -2.72M | 1.27M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 19, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 19, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 4, 2026 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Mar 20, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Mar 20, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Mar 20, 2026 | Meeting notice | SEC |
| 8-K · Current report | Mar 18, 2026 | Results | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-K · Annual report | Mar 18, 2026 | Annual report | SEC |
| PRE 14A · Preliminary proxy statement | Mar 10, 2026 | Meeting notice | SEC |
| 8-K · Current report | Feb 9, 2026 | Current report | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 17, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 14, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Nov 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 6, 2025 | Current report | SEC |
| 8-K · Current report | Aug 26, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 20, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 19, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 18, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Current report | SEC |
| 424B7 · Prospectus | Aug 5, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 17, 2025 | Material contract | SEC |
| 8-K · Current report | Jun 9, 2025 | Meeting outcome | SEC |
| 8-K · Current report | May 20, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 24, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2025 | Meeting notice | SEC |
| 8-K · Current report | Mar 31, 2025 | Results | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2025 | Meeting outcome | SEC |
| 8-K/A · Current report, amended | Mar 4, 2025 | Management or board change | SEC |
| 8-K · Current report | Feb 19, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Feb 4, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Feb 4, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jan 30, 2025 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Jan 21, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Jan 17, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 15, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 15, 2025 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Jan 13, 2025 | Meeting notice | SEC |
| S-3 · Registration statement | Jan 10, 2025 | Offer document | SEC |
| D | Dec 30, 2024 | Other filings | SEC |
| 4 · Change in ownership | Dec 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 23, 2024 | Material contract | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 23, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Dec 19, 2024 | Material contract | SEC |
| 8-K · Current report | Dec 17, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Dec 9, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Dec 6, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 4, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 4, 2024 | Other filings | SEC |
| S-3 · Registration statement | Nov 27, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2024 | Current report | SEC |
| 8-K · Current report | Jun 12, 2024 | Meeting outcome | SEC |
| SC 13D/A · Big-stake notice, amended | May 17, 2024 | Big-stake notice | SEC |
| 8-K · Current report | May 15, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 8, 2024 | Current report | SEC |
| 8-K · Current report | Mar 25, 2024 | Results | SEC |
| 10-K · Annual report | Mar 25, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 1, 2024 | Current report | SEC |
| 8-K · Current report | Feb 26, 2024 | Material contract | SEC |
| 8-K · Current report | Jan 8, 2024 | Current report | SEC |
| 8-K · Current report | Dec 11, 2023 | Current report | SEC |
| 8-K · Current report | Nov 20, 2023 | Management or board change | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Sep 11, 2023 | Current report | SEC |
| 8-K · Current report | Aug 14, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2023 | Current report | SEC |
| 8-K · Current report | Jul 10, 2023 | Current report | SEC |
| 3 · Initial statement of ownership | Jul 5, 2023 | Insider trade | SEC |
| 8-K · Current report | Jul 3, 2023 | Management or board change | SEC |
| 8-K · Current report | Jun 30, 2023 | Acquisition or disposal | SEC |
| 8-K · Current report | Jun 26, 2023 | Current report | SEC |
| 8-K · Current report | Jun 12, 2023 | Current report | SEC |
| 8-K · Current report | Jun 9, 2023 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2023 | Insider trade | SEC |
| 8-K · Current report | May 31, 2023 | Current report | SEC |
| 10-Q · Quarterly report | May 15, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | May 11, 2023 | Insider trade | SEC |
| 8-K · Current report | May 8, 2023 | Current report | SEC |
| 8-K · Current report | May 1, 2023 | Material contract | SEC |
| ARS · Annual report to shareholders | Apr 28, 2023 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 28, 2023 | Meeting notice | SEC |
| 424B5 · Prospectus | Mar 22, 2023 | Offer document | SEC |
| 8-K · Current report | Mar 22, 2023 | Results | SEC |
| 10-K · Annual report | Mar 22, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 16, 2023 | Management or board change | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 3, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2023 | Insider trade | SEC |
| 8-K · Current report | Jan 26, 2023 | Current report | SEC |
| 424B3 · Prospectus | Jan 3, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 3, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 29, 2022 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 29, 2022 | Other filings | SEC |
| S-1 · Registration statement | Dec 23, 2022 | Offer document | SEC |
| 8-K · Current report | Dec 13, 2022 | Material contract | SEC |
| 8-K · Current report | Nov 22, 2022 | Current report | SEC |
| 8-K · Current report | Nov 10, 2022 | Results | SEC |
| 10-Q · Quarterly report | Nov 10, 2022 | Quarterly report | SEC |
| 8-K · Current report | Oct 20, 2022 | Current report | SEC |
| 8-K · Current report | Sep 27, 2022 | Management or board change | SEC |
| 8-K · Current report | Sep 13, 2022 | Current report | SEC |
| 8-K · Current report | Aug 19, 2022 | Current report | SEC |
| S-8 · Registration statement for employee plans | Aug 11, 2022 | Offer document | SEC |
| 8-K · Current report | Aug 11, 2022 | Results | SEC |
| 10-Q · Quarterly report | Aug 11, 2022 | Quarterly report | SEC |
| 8-K · Current report | Aug 4, 2022 | Current report | SEC |
| 8-K · Current report | May 27, 2022 | Meeting outcome | SEC |
| 4 · Change in ownership | May 26, 2022 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2022 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2022 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2022 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2022 | Insider trade | SEC |
| 8-K · Current report | May 13, 2022 | Results | SEC |
| 10-Q · Quarterly report | May 12, 2022 | Quarterly report | SEC |
| 8-K · Current report | Apr 26, 2022 | Material contract | SEC |
| DEF 14A · Proxy statement | Apr 15, 2022 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 6, 2022 | Meeting notice | SEC |
| 8-K · Current report | Apr 6, 2022 | Management or board change | SEC |
| 4 · Change in ownership | Mar 28, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2022 | Insider trade | SEC |
| 424B5 · Prospectus | Mar 18, 2022 | Offer document | SEC |
| 8-K · Current report | Mar 17, 2022 | Results | SEC |
| 10-K · Annual report | Mar 17, 2022 | Annual report | SEC |
| 4 · Change in ownership | Feb 22, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2022 | Insider trade | SEC |
| 8-K · Current report | Feb 18, 2022 | Current report | SEC |
| 8-K · Current report | Feb 16, 2022 | Current report | SEC |
| 8-K · Current report | Jan 19, 2022 | Current report | SEC |
| 4 · Change in ownership | Dec 9, 2021 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 9, 2021 | Insider trade | SEC |
| 8-K · Current report | Dec 9, 2021 | Management or board change | SEC |
| 8-K · Current report | Nov 15, 2021 | Management or board change | SEC |
| 8-K · Current report | Nov 10, 2021 | Results | SEC |
| 10-Q · Quarterly report | Nov 10, 2021 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Aug 20, 2021 | Other filings | SEC |
| 8-K · Current report | Aug 19, 2021 | Current report | SEC |
| CORRESP · Letter to the SEC | Aug 17, 2021 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 17, 2021 | Other filings | SEC |
| S-3 · Registration statement | Aug 10, 2021 | Offer document | SEC |
| 8-K · Current report | Aug 10, 2021 | Results | SEC |
| 10-Q · Quarterly report | Aug 10, 2021 | Quarterly report | SEC |
| 8-K · Current report | Jul 28, 2021 | Current report | SEC |
| 8-K · Current report | Jul 6, 2021 | Current report | SEC |
| 8-K · Current report | Jun 11, 2021 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 10, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2021 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2021 | Insider trade | SEC |
| 8-K · Current report | May 12, 2021 | Results | SEC |
| 10-Q · Quarterly report | May 12, 2021 | Quarterly report | SEC |
| DEFR14A | May 5, 2021 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2021 | Meeting notice | SEC |
This page holds 200 of 906 filings. Open Filings
Cap table
Built by 6ix from Marker Therapeutics, Inc.’s releases · as of Nov 13, 2026
- Common shares
- 16,673,127
- Fully diluted
- 16,673,127
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 16,673,127 | Nov 13, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 13, 2026 | 16,673,127 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Joshua N. Silverman Other companies: Femasys Inc. (Director · Since at least Nov 21, 2023); PharmaCyte Biotech, Inc. (Interim Chief Executive Officer, President, and Director · Since at least Aug 15, 2022); TAO Synergies Inc. (Executive Chairman · Since at least Jun 4, 2021); Petros Pharmaceuticals Inc (Vice-Chairman of the Board · Since at least Dec 1, 2020); Q/C Technologies, Inc. (Executive Chairman · Since at least Sep 6, 2018); Fabric.AI, Inc. (Chief Executive Officer, Director · Since at least Aug 15, 2016); Neurotrope Inc (Director · Aug 4, 2016 – Dec 1, 2020 · Past); Protagenic Therapeutics, Inc. (Director · Feb 12, 2016 – Feb 21, 2020 · Past); MGT Capital Investments, Inc. (Director · Dec 31, 2015 – Dec 31, 2015 · Past); National Holdings Corporation (Director · Jul 28, 2014 – Sep 12, 2016 · Past) | Director · Nov 28, 2016 – Oct 16, 2018 · Past |
| Steven A. Elms Other companies: Elevation Oncology Inc (Director · Since at least Jun 17, 2022); ADMA Biologics Inc (Chairman · Since at least Feb 13, 2012); Zosano Pharma Corp (Director · May 17, 2018 – Jun 10, 2021 · Past); T2 Biosystems, Inc. (Director · Dec 9, 2015 – Dec 9, 2015 · Past); Cidara Therapeutics Inc (Director · Apr 14, 2015 – Apr 20, 2015 · Past); Loxo Oncology Inc (Director · Jul 31, 2014 – Feb 15, 2019 · Past); Ambit Biosciences Corp (Director · May 15, 2013 – Sep 2, 2014 · Past); Pernix Therapeutics Holdings Inc (Director · Aug 31, 2011 – May 26, 2016 · Past) | Director · Since at least Aug 6, 2019 |
| Frederick G. Wasserman Other companies: DLH Holdings Corp. (Chairman of the Board of Directors · Since at least Oct 3, 2007); National Holdings Corporation (Director · Sep 12, 2016 – Sep 12, 2016 · Past); SMTC Corporation (Director · Feb 4, 2015 – Apr 5, 2021 · Past); Gilman Ciocia Inc (Director · Oct 3, 2008 – Oct 15, 2013 · Past); Breeze-Eastern Corp (Director · Sep 13, 2007 – Jan 4, 2016 · Past); Crown Crafts, Inc. (Director · Aug 29, 2007 – Aug 12, 2009 · Past); MAM Software Group Inc (Director · Jul 17, 2007 – Oct 21, 2019 · Past) | Director · Jan 26, 2016 – Jun 8, 2021 · Past |
| Paul Edward Walker Other companies: NeueHealth Inc (Director · Since at least Oct 2, 2025); Trillium Therapeutics Inc (Director · Jan 1, 2021 – Nov 17, 2021 · Past); Regulus Therapeutics Inc (Director · May 7, 2019 – May 7, 2019 · Past); Trevi Therapeutics, Inc. (Director · May 7, 2019 – May 7, 2019 · Past); Allakos Inc (Director · Jul 18, 2018 – May 15, 2025 · Past); Tesaro Inc (Director · Jun 27, 2012 – Jun 2, 2014 · Past) | Director · Oct 17, 2018 – Oct 17, 2018 · Past |
| John N Bonfiglio Other companies: Qrons Inc (Chief Operating Officer · Jul 1, 2019 – Jul 1, 2019 · Past); Genprex, Inc. (Director · Feb 12, 2019 – Feb 12, 2019 · Past); Oragenics Inc. (President and CEO, Director · May 25, 2011 – Aug 13, 2014 · Past); Harrow, Inc. (President and CEO, Director · Oct 20, 2010 – Oct 20, 2010 · Past) | President and COO, Director · Jul 23, 2015 – Mar 9, 2017 · Past |
| Katharine Knobil Other companies: Korro Bio, Inc. (Director · Since at least Aug 26, 2024); Pliant Therapeutics, Inc. (Director · Since at least Sep 14, 2022); Arena Pharmaceuticals Inc (Director · Jun 12, 2020 – Mar 11, 2022 · Past); Kaleido Biosciences, Inc. (Chief Medical Officer · Feb 27, 2019 – Oct 15, 2020 · Past) | Chief Medical Officer, Altesa BioSciences, Inc. · Since at least Dec 8, 2021 |
| Eliot M Lurier Other companies: Mustang Bio, Inc. (Interim CFO · Apr 18, 2022 – Apr 18, 2022 · Past); Tenax Therapeutics, Inc. (Interim CFO · Oct 29, 2021 – Oct 29, 2021 · Past); Interleukin Genetics Inc (Chief Financial Officer · Mar 23, 2011 – Oct 22, 2013 · Past) | Interim CFO · Jun 30, 2023 – Jun 30, 2023 · Past |
| Glynn Wilson Other companies: Caring Brands, Inc. (Chief Executive Officer, Director · Since at least Oct 30, 2025); Cadrenal Therapeutics, Inc. (Board Member · Since at least Jan 19, 2023); Bonk, Inc. (Former CSO, Chairman, Director · Oct 30, 2020 – Mar 1, 2024 · Past) | Director · Jun 8, 2007 – Oct 9, 2018 · Past |
| Sherry Grisewood Other companies: PetVivo Holdings Inc (Director · Aug 20, 2018 – Jan 15, 2019 · Past); Oncolix Inc (Director · Jun 26, 2018 – Jun 26, 2018 · Past) | Director · Nov 12, 2015 – Oct 16, 2018 · Past |
| Ann M Leen Other companies: Kalaris Therapeutics, Inc. (Chief Scientific Officer · Jul 29, 2020 – Aug 16, 2022 · Past) | Chief Scientific Officer · Dec 21, 2018 – Feb 15, 2020 · Past |
All 33 people
| Person | Seat |
|---|---|
| Denis Corin Other companies: Q BioMed Inc (Chief Executive Officer, Director · Apr 21, 2015 – May 26, 2022 · Past) | President, Director · Jun 8, 2007 – Feb 17, 2012 · Past |
| John Robert Wilson Other companies: Kalaris Therapeutics, Inc. (Director · Jul 29, 2020 – May 25, 2021 · Past) | Director · Oct 17, 2018 – Jun 6, 2023 · Past |
| Juan F. Vera Other companies: Kalaris Therapeutics, Inc. (Director · Jul 29, 2020 – Jun 6, 2024 · Past) | Chief Executive Officer & Co-Founder, Marker Therapeutics · Since at least Oct 17, 2018 |
| Kathryn Penkus Corzo Other companies: Matinas BioPharma Holdings, Inc. (Director · Nov 1, 2021 – Nov 1, 2023 · Past) | President and Chief Operating Officer, bit.bio · Since at least Oct 31, 2025 |
| Ken Moseley Other companies: Bellicum Pharmaceuticals Inc (Sr. VP and General Counsel · Dec 17, 2014 – Jan 3, 2018 · Past) | General Counsel · Dec 21, 2018 – Dec 21, 2018 · Past |
| Norman David Eansor Other companies: Bio-Techne Corp (President-Protein Sciences · Jun 12, 2019 – Nov 12, 2021 · Past) | Director · Since at least May 9, 2019 |
| Anna Szymanska | Vice President, Quality · Mar 10, 2020 – Feb 27, 2023 · Past |
| Anthony H Kim | Chief Financial Officer · Nov 27, 2018 – Mar 24, 2022 · Past |
| David Eansor | Director · Since at least Nov 5, 2026 |
| Edmund Cheung | Vice President, Human Resources · Since at least Nov 4, 2026 |
| Gerald Garrett | Vice President, Clinical Ops. · Mar 10, 2020 – Feb 17, 2022 · Past |
| Lynn DePippo | Director · Sep 7, 2010 – Sep 7, 2010 · Past |
| Mark Reddish | Director · Feb 17, 2012 – Oct 16, 2018 · Past |
| Mary Newman | Head of Regulatory Affairs · Since at least Nov 5, 2026 |
| Michael Loiacono | Chief Accounting Officer · Aug 25, 2016 – Feb 27, 2023 · Past |
| Mythili Koneru | Chief Medical Officer · May 9, 2019 – Feb 27, 2023 · Past |
| Nadia Agopyan | SVP, Regulatory Affairs · Aug 15, 2019 – Feb 27, 2023 · Past |
| Patricia Allison | Head of Clinical Operations · Since at least Nov 4, 2026 |
| Patrick A McGowan | Secretary, Treasurer & CFO, Director · Jun 8, 2007 – Jun 8, 2007 · Past |
| Peter L Hoang | President and CEO, Director · Aug 14, 2019 – Mar 24, 2022 · Past |
| Steve Elms | Managing Partner, Aisling Capital · Since at least Nov 4, 2026 |
| Tracy A Moore | Chief Financial Officer, Director · Aug 24, 2009 – Oct 14, 2009 · Past |
| Tsvetelina P Hoang | VP, Research and Development · Dec 21, 2018 – Feb 27, 2023 · Past |
Log in to ask 6ix AI your own questions about Marker Therapeutics, Inc.